NVDA   385.50 (+1.13%)
GE   6.88 (+1.93%)
NVDA   385.50 (+1.13%)
GE   6.88 (+1.93%)
NVDA   385.50 (+1.13%)
GE   6.88 (+1.93%)
NVDA   385.50 (+1.13%)
GE   6.88 (+1.93%)
Log in

NYSE:ELOXSenesco Technologies Stock Price, Forecast & News

$3.03
-0.05 (-1.62 %)
(As of 07/2/2020 08:54 AM ET)
Add
Compare
Today's Range
$2.93
Now: $3.03
$3.09
50-Day Range
$2.45
MA: $3.18
$3.65
52-Week Range
$1.44
Now: $3.03
$10.00
Volume65,000 shs
Average Volume155,851 shs
Market Capitalization$121.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone781-577-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$121.59 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive ELOX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.

Senesco Technologies (NYSE:ELOX) Frequently Asked Questions

How has Senesco Technologies' stock been impacted by COVID-19 (Coronavirus)?

Senesco Technologies' stock was trading at $2.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ELOX stock has increased by 5.2% and is now trading at $3.03. View which stocks have been most impacted by Coronavirus.

When is Senesco Technologies' next earnings date?

Senesco Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Senesco Technologies.

How were Senesco Technologies' earnings last quarter?

Senesco Technologies Inc. (NYSE:ELOX) posted its earnings results on Thursday, May, 7th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.06. View Senesco Technologies' earnings history.

Has Senesco Technologies been receiving favorable news coverage?

Headlines about ELOX stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Senesco Technologies earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Senesco Technologies.

Who are some of Senesco Technologies' key competitors?

What other stocks do shareholders of Senesco Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Senesco Technologies investors own include Aclaris Therapeutics (ACRS), Acorda Therapeutics (ACOR), Achieve Life Sciences (ACHV), ADMA Biologics (ADMA), Agenus (AGEN), AIM ImmunoTech (AIM), Accuray (ARAY), Cidara Therapeutics (CDTX), Canopy Growth (CGC) and Celldex Therapeutics (CLDX).

Who are Senesco Technologies' key executives?

Senesco Technologies' management team includes the following people:
  • Mr. Robert E. Ward, Chairman & CEO (Age 61)
  • Dr. Silvia Noiman, Founder & Director (Age 62)
  • Mr. Gregory L. Weaver CPA, M.B.A., Chief Financial Officer (Age 62)
  • Dr. Gregory Williams, COO & Interim Chief Medical Officer (Age 59)
  • Ms. Barbara Ryan, Investor Relations Officer

What is Senesco Technologies' stock symbol?

Senesco Technologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELOX."

How do I buy shares of Senesco Technologies?

Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Senesco Technologies' stock price today?

One share of ELOX stock can currently be purchased for approximately $3.03.

How big of a company is Senesco Technologies?

Senesco Technologies has a market capitalization of $121.59 million.

What is Senesco Technologies' official website?

The official website for Senesco Technologies is www.eloxxpharma.com.

How can I contact Senesco Technologies?

The company can be reached via phone at 781-577-5300.

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.